About Genomenon
Genomenon is a private company based in Ann Arbor, Michigan. It has reported $34,818,635 raised in five offerings on Form D since August 2015. Its chief executive is Michael Klein.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jul 15, 2026 | Jul 30, 2026 | $6,025,002of $10.0M target | 30 | $200K | EquityRule 506(b) | Form D ↗ |
| May 1, 2024 | May 16, 2024 | $5,461,759of $6.0M target | 30 | $182K | EquityRule 506(b) | Form D ↗ |
| Feb 24, 2022 | Mar 10, 2022 | $19,999,994fully sold | 23 | $869K | EquityRule 506(b) | Form D ↗ |
| May 15, 2020 | May 21, 2020 | $2,885,877of $3.0M target | 36 | $80,163 | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Aug 6, 2015 | Aug 14, 2015 | $446,003of $1.0M target | 11 | $40,546 | EquityRule 506(b) | Form D ↗ |
| Total, five offerings | $34,818,635 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Genomenon's Form D filed Jul 30, 2026.
Earlier filings also listed Sean Kearney (chief financial officer, last listed May 2024), Steve Schwartz (executive officer, last listed May 2020), Charles Moret (director, last listed May 2020), Sonya Sepahban (director, last listed Aug 2015) and Eli Salembier (executive officer and director, last listed Aug 2015).
Sources
- SECGenomenon, Inc. filing history
- CompanyGenomenon contact
- CompanyGenomenon leadership